PTPRC and acute myeloid leukemia: Iomab-B is another 131I-radiolabeled antibody (apamistamab, an anti-CD45 mAb) used in multiple blood cancer indications (32), which is currently investigated in the SIERRA phase 3 study (NCT02665065), in patients with relapsed or refractory acute myeloid leukemia (AML).